William Blair Reduces Earnings Estimates for Climb Bio

Climb Bio, Inc. (NASDAQ:CLYM) – Equities researchers at William Blair reduced their FY2027 earnings per share (EPS) estimates for Climb Bio in a research note issued on Monday, November 10th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($1.06) per share for the year, down from their prior estimate of ($0.88). William Blair has a “Outperform” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for Climb Bio’s FY2028 earnings at ($1.30) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03).

Several other equities analysts have also recently issued reports on CLYM. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Climb Bio in a report on Thursday, October 16th. Wall Street Zen cut shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research report on Saturday. HC Wainwright initiated coverage on shares of Climb Bio in a research note on Monday, October 13th. They issued a “buy” rating and a $9.00 price objective on the stock. Robert W. Baird assumed coverage on shares of Climb Bio in a research report on Friday, August 15th. They set an “outperform” rating and a $9.00 target price for the company. Finally, Baird R W raised Climb Bio to a “strong-buy” rating in a research note on Friday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $9.20.

Climb Bio Stock Up 1.8%

NASDAQ:CLYM traded up $0.04 during trading hours on Wednesday, hitting $1.94. 39,553 shares of the stock were exchanged, compared to its average volume of 429,254. The company’s 50 day moving average is $2.07 and its two-hundred day moving average is $1.68. The company has a market capitalization of $131.93 million, a P/E ratio of -2.55 and a beta of -0.06. Climb Bio has a twelve month low of $1.05 and a twelve month high of $4.04.

Hedge Funds Weigh In On Climb Bio

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC bought a new stake in Climb Bio during the 1st quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Climb Bio in the third quarter valued at approximately $29,000. XTX Topco Ltd acquired a new position in shares of Climb Bio in the first quarter valued at approximately $34,000. Qube Research & Technologies Ltd bought a new stake in shares of Climb Bio during the second quarter worth $43,000. Finally, Marshall Wace LLP bought a new stake in shares of Climb Bio during the second quarter worth $46,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.